(1.08%) 5 118.64 points
(1.23%) 38 695 points
(1.78%) 16 124 points
(-0.25%) $78.75
(0.64%) $2.05
(-0.50%) $2 298.00
(-1.24%) $26.50
(0.22%) $964.70
(-0.44%) $0.928
(-1.34%) $10.84
(-0.23%) $0.796
(0.15%) $91.26
2.00% £ 153.00
Live Chart Being Loaded With Signals
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine...
Stats | |
---|---|
Dzisiejszy wolumen | 8 165.00 |
Średni wolumen | 31 797.00 |
Kapitalizacja rynkowa | 110.17M |
EPS | £0 ( 2024-03-13 ) |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -3.73 |
ATR14 | £4.42 (2.89%) |
Faron Pharmaceuticals Oy Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Faron Pharmaceuticals Oy Finanse
Annual | 2023 |
Przychody: | £0 |
Zysk brutto: | £0 (0.00 %) |
EPS: | £-0.480 |
FY | 2023 |
Przychody: | £0 |
Zysk brutto: | £0 (0.00 %) |
EPS: | £-0.480 |
FY | 2022 |
Przychody: | £0 |
Zysk brutto: | £0 (0.00 %) |
EPS: | £-0.590 |
FY | 2021 |
Przychody: | £0.00 |
Zysk brutto: | £0.00 (0.00 %) |
EPS: | £-0.420 |
Financial Reports:
No articles found.
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej